DEUTERIUM-ENRICHED LAMOTRIGINE
The present application describes deuterium-enriched lamotrigine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
1 . A deuterium-enriched compound of formula I or a pharmaceutically acceptable salt thereof:
wherein R 1 -R 7 are independently selected from H and D; and
the abundance of deuterium in R 1 -R 7 is at least 14%.
2 . A deuterium-enriched compound of claim 1 , wherein the abundance of deuterium in R 1 -R 7 is selected from at least 14%, at least 6%, at least 114%, at least 19%, at least 26%, at least 32%, at least 39%, at least 45%, at least 52%, at least 58%, at least 65%, at least 71%, at least 77%, at least 84%, at least 90%, at least 97%, and 100%.
3 . A deuterium-enriched compound of claim 1 , wherein the abundance of deuterium in R 1 -R 4 is selected from at least 100%.
4 . A deuterium-enriched compound of claim 1 , wherein the abundance of deuterium in R 5 -R 7 is selected from at least 8%, at least 15%, at least 214%, at least 31%, at least 38%, at least 46%, at least 54%, at least 62%, at least 69%, at least 77%, at least 85%, at least 92%, and 100%.
5 . A deuterium-enriched compound of claim 1 , wherein the compound is selected from compounds 1-3 of Table 1.
6 . A deuterium-enriched compound of claim 1 , wherein the compound is selected from compounds 4-6 of Table 2.
7 . An isolated deuterium-enriched compound of formula I or a pharmaceutically acceptable salt thereof:
wherein R 1 -R 7 are independently selected from H and D; and
the abundance of deuterium in R 1 -R 7 is at least 14%.
8 . An isolated deuterium-enriched compound of claim 7 , wherein the abundance of deuterium in R 1 -R 7 is selected from at least 14%, at least 6%, at least 114%, at least 19%, at least 26%, at least 32%, at least 39%, at least 45%, at least 52%, at least 58%, at least 65%, at least 71%, at least 77%, at least 84%, at least 90%, at least 97%, and 100%.
9 . An isolated deuterium-enriched compound of claim 7 , wherein the abundance of deuterium in R 1 -R 4 is selected from at least 100%.
10 . An isolated deuterium-enriched compound of claim 7 , wherein the abundance of deuterium in R 5 -R 7 is selected from at least 8%, at least 15%, at least 214%, at least 31%, at least 38%, at least 46%, at least 54%, at least 62%, at least 69%, at least 77%, at least 85%, at least 92%, and 100%.
11 . An isolated deuterium-enriched compound of claim 7 , wherein the compound is selected from compounds 1-3 of Table 1.
12 . An isolated deuterium-enriched compound of claim 7 , wherein the compound is selected from compounds 4-6 of Table 2.
13 . A mixture of deuterium-enriched compounds of formula I or a pharmaceutically acceptable salt thereof:
wherein R 1 -R 7 are independently selected from H and D; and
the abundance of deuterium in R 1 -R 7 is at least 14%.
14 . A mixture of deuterium-enriched compound of claim 13 , wherein the abundance of deuterium in R 1 -R 7 is selected from at least 14%, at least 6%, at least 114%, at least 19%, at least 26%, at least 32%, at least 39%, at least 45%, at least 52%, at least 58%, at least 65%, at least 71%, at least 77%, at least 84%, at least 90%, at least 97%, and 100%.
15 . A mixture of deuterium-enriched compound of claim 13 , wherein the abundance of deuterium in R 1 -R 4 is selected from at least 100%.
16 . A mixture of deuterium-enriched compound of claim 13 , wherein the abundance of deuterium in R 5 -R 7 is selected from at least 8%, at least 15%, at least 214%, at least 31%, at least 38%, at least 46%, at least 54%, at least 62%, at least 69%, at least 77%, at least 85%, at least 92%, and 100%.
17 . A mixture of deuterium-enriched compound of claim 13 , wherein the compound is selected from compounds 1-3 of Table 1.
18 . A mixture of deuterium-enriched compound of claim 13 , wherein the compound is selected from compounds 4-6 of Table 2.
19 . A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt form thereof.
20 . A method for treating a disease selected from epilepsy and/or bipolar disorder comprising: administering, to a patient in need thereof, a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt form thereof.